Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$830M |
| 2 |
UnitedHealth
UNH
|
+$769M |
| 3 |
Arthur J. Gallagher & Co
AJG
|
+$691M |
| 4 |
Amazon
AMZN
|
+$654M |
| 5 |
Bank of America
BAC
|
+$634M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.23B |
| 2 |
NVIDIA
NVDA
|
+$550M |
| 3 |
Spotify
SPOT
|
+$473M |
| 4 |
Citigroup
C
|
+$460M |
| 5 |
Boston Scientific
BSX
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 82.83% |
| 2 | Healthcare | 3.13% |
| 3 | Technology | 2.97% |
| 4 | Financials | 2.19% |
| 5 | Consumer Discretionary | 2.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
XHR
13701
PUT
Xenia Hotels & Resorts
XHR
$1.67B
| $7.43K | ﹤0.01% |
+500
| New | +$7.56K |
2024 Q4
0 quarters
|
|
13702
CALL
iShares MSCI Brazil Small-Cap ETF
EWZS
$278M
| $7.4K | ﹤0.01% |
800
-4,000
| -83% | -$45.1K |
2024 Q3
1 quarter
|
|
13703
PUT
IRIDEX
IRIX
$12.1M
| $7.39K | ﹤0.01% |
4,400
-3,400
| -44% | -$5.61K |
2023 Q3
5 quarters
|
|
|
LPAAW
13704
Launch One Acquisition Corp Warrant
LPAAW
| $7.35K | ﹤0.01% |
54,467
-699
| -1% | -$67 |
2024 Q3
1 quarter
|
|
13705
PUT
Capital City Bank Group
CCBG
$844M
| $7.33K | ﹤0.01% |
200
-200
| -50% | -$7.38K |
2023 Q4
4 quarters
|
|
13706
CALL
Beyond Air
XAIR
$2.8M
| $7.31K | ﹤0.01% |
51
+1
| +2% | +$179 |
2021 Q1
15 quarters
|
|
13707
PUT
Bionano Genomics
BNGO
$17.1M
| $7.25K | ﹤0.01% |
419
-307
| -42% | -$5.25K |
2021 Q1
15 quarters
|
|
|
HOOK
13708
CALL
DELISTED
HOOKIPA Pharma
HOOK
| $7.24K | ﹤0.01% |
3,600
+1,220
| +51% | +$3.77K |
2024 Q1
3 quarters
|
|
13709
PUT
NB Bancorp
NBBK
$982M
| $7.22K | ﹤0.01% |
400
| – | – |
2024 Q2
2 quarters
|
|
13710
CALL
iShares MSCI All Country Asia ex Japan ETF
AAXJ
$4.06B
| $7.22K | ﹤0.01% |
+100
| New | +$7.6K |
2024 Q4
0 quarters
|
|
|
INZY
13711
CALL
DELISTED
Inozyme Pharma
INZY
| $7.2K | ﹤0.01% |
2,600
-1,100
| -30% | -$4.18K |
2023 Q1
7 quarters
|
|
13712
PUT
Commercial Vehicle Group
CVGI
$122M
| $7.19K | ﹤0.01% |
2,900
-4,300
| -60% | -$11.5K |
2023 Q4
4 quarters
|
|
13713
Abeona Therapeutics
ABEO
$292M
| $7.14K | ﹤0.01% |
1,282
+573
| +81% | +$3.53K |
2023 Q4
4 quarters
|
|
13714
PUT
Arteris
AIP
$1.18B
| $7.13K | ﹤0.01% |
700
-4,600
| -87% | -$38K |
2023 Q1
7 quarters
|
|
13715
CALL
Bank of Marin Bancorp
BMRC
$444M
| $7.13K | ﹤0.01% |
300
+100
| +50% | +$2.36K |
2023 Q2
6 quarters
|
|
13716
PUT
PharmaCyte Biotech
PMCB
$4.19M
| $7.13K | ﹤0.01% |
+4,600
| New | +$7.94K |
2024 Q4
0 quarters
|
|
|
GURE
13717
Gulf Resources
GURE
$5.6M
| $7.13K | ﹤0.01% |
+1,261
| New | +$8.63K |
2024 Q4
0 quarters
|
|
13718
PUT
Hanmi Financial
HAFC
$934M
| $7.09K | ﹤0.01% |
300
| – | – |
2022 Q4
8 quarters
|
|
13719
PUT
Dynagas LNG Partners
DLNG
$137M
| $7.07K | ﹤0.01% |
+1,300
| New | +$5.55K |
2024 Q4
0 quarters
|
|
13720
PUT
iShares MSCI EAFE Min Vol Factor ETF
EFAV
$5.26B
| $7.07K | ﹤0.01% |
+100
| New | +$7.36K |
2024 Q4
0 quarters
|
|
13721
Addentax Group
ATXG
$4.01M
| $7.06K | ﹤0.01% |
+768
| New | +$7.35K |
2024 Q4
0 quarters
|
|
|
YMAB
13722
PUT
DELISTED
Y-mAbs Therapeutics
YMAB
| $7.05K | ﹤0.01% |
900
+500
| +125% | +$6.09K |
2023 Q4
4 quarters
|
|
|
GRSD
13723
PUT
Grandstand Ltd
GRSD
$55.2M
| $7.04K | ﹤0.01% |
500
-2,700
| -84% | -$31.8K |
2023 Q2
6 quarters
|
|
13724
NeuroSense Therapeutics Warrant
NRSNW
$920K
| $7.04K | ﹤0.01% |
22,711
-2,563
| -10% | -$685 |
2024 Q1
3 quarters
|
|
13725
CALL
Adicet Bio
ACET
$60.6M
| $7.02K | ﹤0.01% |
456
+193
| +73% | +$3.64K |
2022 Q2
10 quarters
|
|
Similar funds
Citadel Advisors's Q4 2024 Portfolio in Review
As of Q4 2024, Citadel Advisors held 15,826 positions worth $578B, up 11% from $518B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Citadel Advisors's Q4 2024 filing shows 1,745 new, 6,427 increased, 6,082 reduced and 1,421 closed positions. Its largest new stake was Zoetis: 1,090,499 shares worth $178M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.23B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 83% a quarter earlier, followed by Healthcare and Technology.
- Citadel Advisors's largest Q4 2024 buy was Zoetis: 1,090,499 shares worth $178M.
- Citadel Advisors added most to Boeing in Q4 2024, an estimated $830M increase.
- Citadel Advisors's biggest Q4 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.23B.
- Citadel Advisors fully exited Spotify in Q4 2024, selling an estimated $473M.
- Citadel Advisors's ten largest holdings make up 31% of its $578B portfolio in Q4 2024.
- Citadel Advisors opened 1,745 new positions and closed 1,421 in Q4 2024.
- Citadel Advisors's portfolio value rose 11% quarter-over-quarter to $578B.
Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.